Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Achaogen Inc AKAOQ

Healthcare Biotechnology
"Achaogen Inc is a biopharmaceutical company developing novel antibacterial treatments against multi-drug resistant gram-negative infections. The company is researching and developing on its product plazomicin used for the treatment of serious bacterial infections. It's another antibacterial candidate, C-Scape treats patients with urinary tract infections. All of the company's revenue is... see more

Recent & Breaking News (OTCPK:AKAOQ)

Achaogen Adds Janet Dorling as Chief Commercial Officer

GlobeNewswire February 27, 2017

Achaogen Announces Leadership Promotions

GlobeNewswire February 23, 2017

Achaogen Announces Achievement of a Key Milestone in Developing a Plazomicin Assay to Support Therapeutic Drug Management (TDM)

GlobeNewswire February 22, 2017

Research Reports Initiation on Biotech Stocks -- Heat Biologics, PDL BioPharma, Achaogen, and CEL-SCI

PR Newswire February 16, 2017

Achaogen to Host R&D Day Focused on Advances and Opportunities in the Treatment of Resistant Gram-Negative Infections

GlobeNewswire February 15, 2017

Achaogen to Participate in the Leerink Partners 6th Annual Global Healthcare Conference

GlobeNewswire February 9, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  January 11, 2017

Achaogen Appoints Halley Gilbert to Its Board of Directors

GlobeNewswire January 5, 2017

18 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  January 4, 2017

The Market In 5 Minutes: Trump's Impact Continues

Benzinga.com  January 4, 2017

18 Biggest Mid-Day Losers For Wednesday

Benzinga.com  December 14, 2016

Achaogen Announces Pricing of Public Offering of Common Stock

GlobeNewswire December 14, 2016

20 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  December 14, 2016

Achaogen's Phase 3 Shows 'Best Case Scenario'

Benzinga.com  December 13, 2016

10 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  December 13, 2016

Mid-Morning Market Update: Markets Open Higher; VeriFone Issues Weak Forecast

Benzinga.com  December 13, 2016

Biotech Companies Continue Quest for Advanced Drug Developments

PR Newswire December 13, 2016

Mid-Afternoon Market Update: Achaogen Surges On Positive Phase 3 Results; Alexion Shares Slide

Benzinga.com  December 12, 2016

18 Biggest Mid-Day Gainers For Monday

Benzinga.com  December 12, 2016

Mid-Day Market Update: Crude Oil Up Over 3%; Ophthotech Shares Tumble After Failed Phase 3 Trial Of Fovista

Benzinga.com  December 12, 2016